{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Regular+insulin+U-100&page=2", "query": { "intervention": "Regular insulin U-100", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Regular+insulin+U-100&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T00:53:39.330Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05462756", "title": "A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes", "Type 2 Diabetes Treated With Insulin" ], "interventions": [ { "name": "Insulin Efsitora Alfa", "type": "DRUG" }, { "name": "Insulin Lispro (U100)", "type": "DRUG" }, { "name": "Insulin Glargine (U100)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 730, "start_date": "2022-08-11", "completion_date": "2024-02-27", "has_results": true, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-09-29T00:53:39.330Z", "location_count": 24, "location_summary": "Hamden, Connecticut • Clearwater, Florida • Miami Lakes, Florida + 19 more", "locations": [ { "city": "Hamden", "state": "Connecticut" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "Weston", "state": "Florida" }, { "city": "Blackfoot", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT05462756" }, { "nct_id": "NCT03336528", "title": "Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Degludec", "type": "DRUG" }, { "name": "Glargine", "type": "DRUG" }, { "name": "Aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2018-01-02", "completion_date": "2021-03-01", "has_results": true, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-09-29T00:53:39.330Z", "location_count": 4, "location_summary": "Atlanta, Georgia • New York, New York • Spokane, Washington", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03336528" }, { "nct_id": "NCT01676220", "title": "Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "HOE901-U300 (new formulation of insulin glargine)", "type": "DRUG" }, { "name": "Lantus (insulin glargine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 878, "start_date": "2012-08", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2015-06-24", "last_synced_at": "2026-09-29T00:53:39.330Z", "location_count": 117, "location_summary": "Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 93 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01676220" }, { "nct_id": "NCT02688933", "title": "A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "HOE901-U300 (Insulin Glargine 300 U/ml)", "type": "DRUG" }, { "name": "Lantus (Insulin Glargine 100 U/ml)", "type": "DRUG" }, { "name": "Mandated back ground therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 638, "start_date": "2016-05-05", "completion_date": "2017-06-19", "has_results": true, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-09-29T00:53:39.330Z", "location_count": 99, "location_summary": "Little Rock, Arkansas • Concord, California • Escondido, California + 80 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Concord", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02688933" }, { "nct_id": "NCT03737240", "title": "IDegLira HIGH Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "IDegLira", "type": "DRUG" }, { "name": "Insulin Degludec (U-100)", "type": "DRUG" }, { "name": "Insulin Aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 145, "start_date": "2019-01-15", "completion_date": "2022-07-08", "has_results": true, "last_update_posted_date": "2023-09-08", "last_synced_at": "2026-09-29T00:53:39.330Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03737240" }, { "nct_id": "NCT01240252", "title": "Insulin Receptor Substrate 1 (IRS-1) Regulation in Insulin Resistance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Human insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "30 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "30 Years to 65 Years" }, "enrollment_count": 14, "start_date": "2012-03", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2013-06-05", "last_synced_at": "2026-09-29T00:53:39.330Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01240252" }, { "nct_id": "NCT01683266", "title": "Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "HOE901-U300 (Insulin glargine new formulation)", "type": "DRUG" }, { "name": "Lantus (Insulin glargine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 549, "start_date": "2012-09", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2015-06-24", "last_synced_at": "2026-09-29T00:53:39.330Z", "location_count": 82, "location_summary": "Chandler, Arizona • Little Rock, Arkansas • Bell Gardens, California + 71 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bell Gardens", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01683266" }, { "nct_id": "NCT01499082", "title": "Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "HOE901-U300 (new formulation of insulin glargine)", "type": "DRUG" }, { "name": "Lantus (insulin glargine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 807, "start_date": "2011-12", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2022-03-25", "last_synced_at": "2026-09-29T00:53:39.330Z", "location_count": 95, "location_summary": "Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 78 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01499082" }, { "nct_id": "NCT01499095", "title": "Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Lantus (Insulin glargine)", "type": "DRUG" }, { "name": "HOE901-U300 (new formulation of insulin glargine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 811, "start_date": "2011-12", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2022-03-23", "last_synced_at": "2026-09-29T00:53:39.330Z", "location_count": 110, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 90 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01499095" }, { "nct_id": "NCT03874715", "title": "Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin Aspart SAR341402", "type": "DRUG" }, { "name": "Insulin Aspart", "type": "DRUG" }, { "name": "Insulin glargine U100", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2019-03-11", "completion_date": "2020-07-08", "has_results": true, "last_update_posted_date": "2024-04-17", "last_synced_at": "2026-09-29T00:53:39.330Z", "location_count": 33, "location_summary": "Concord, California • Temecula, California • Ventura, California + 30 more", "locations": [ { "city": "Concord", "state": "California" }, { "city": "Temecula", "state": "California" }, { "city": "Ventura", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Waterbury", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03874715" } ] }